60096 Federal Register / Vol. 62, No. 215 / Thursday, November 6, 1997 / Notices

is hereby given of the following

National Cancer Institute Special

Emphasis Panel (SEP) meeting:

Name of SEP: Preclinical Toxicology

Studies of Chemopreventive Agenda.

Date: November 14, 1997.

Time: 9:00 a.m. to Adjournment.

Place: Executive Plaza North, Conference

Room J, 6130 Executive Boulevard, Bethesda,

MD 20892.

Contact Person: Lalita Palekar, Ph.D.,

Scientific Review Administrator, National

Cancer Institute, NIH, 6130 Executive

Boulevard, EPN, Room 622B, Bethesda, MD

20892–7405, Telephone: 301/496–7575.

Purpose/Agenda: To review, discuss and

evaluate responses to a Request for Proposal.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.

Proposals and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material and

personal information concerning individuals

associated with the applications, the

disclosure of which would constitute a

clearly unwarranted invasion of personal

privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394; Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control)

Dated: October 30, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–29360 Filed 11–5–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Cancer Institute Special

Emphasis Panel (SEP) meeting:

Name of SEP: Phase III Science Enrichment

Program (Telephone Conference Call).

Date: November 17, 1997.

Time: 8:00 a.m. to Adjournment.

Place: National Cancer Institute, Executive

Plaza North, Conference Room C, 6130

Executive Boulevard, Bethesda, MD 20892.

Contact Person: Wilna Woods, Ph.D.,

Scientific Review Administrator, National

Cancer Institute, NIH, Executive Plaza North,

Room 622B, 6130 Executive Boulevard, MSC

7405, Bethesda, MD 20892–7405, Telephone:

301/496–7903.

Purpose/Agenda: To review, discuss and

evaluate responses to Request for Proposal.

This notice is being published less than 15

days to the meeting due to the urgent need

to meet timing limitations imposed by the

review and funding cycle.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Proposals and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material and

personal information concerning individuals

associated with the proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control)

Dated: October 30, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–29363 Filed 11–5–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Meeting

Pursuant to Section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

National Cancer Institute (NCI) Board of

Scientific Advisors on November 13–14,

1997 in Conference Room 10, Building

31C, National Institutes of Health, 9000

Rockville Pike, Bethesda, Maryland.

This meeting will be open on

November 13 from 8 a.m. to recess and

on November 14 from 8:00 a.m. to

adjournment. Agenda items will include

the following: NCI Director’s Report;

Deputy Director of Extramural Science’s

Reports; Legislative Update; Scientific

Presentation(s); Concept Reviews;

program review updates and reports,

and discussions pertaining to new and

ongoing Board business. Attendance by

the public will be limited to space

available.

Individuals who plan to attend and

need special assistance such as sign

language interpretation or other

reasonable accommodations and

additional information pertaining to the

meeting should contact Dr. Paulette S.

Gray, Executive Secretary, NCI Board of

Scientific Advisors, 6130 Executive

Blvd., EPN, Rm. 600C, Bethesda, MD

20892 (301–496–4218).

This notice is being published less

than 15 days prior to the meeting due

to the urgent need to meet timing

limitations imposed by the review and

funding cycle.

Dated: October 30, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–29364 Filed 11–5–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Meeting

Purusant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meeting

of the National Cancer Institute,

Frederick Cancer Research and

Development Center Advisory

Committee.

The open portion of the meeting will

be limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the contact person in advance of

the meeting.

Committee Name: Frederick Cancer

Research and Development Center Advisory

Committee.

Date: December 11–12, 1997.

Palce: Frederick Cancer Research and

Development Center, Building 549, Executive

Board Room, Frederick, Maryland 21702–

1201.

Open: December 11—8:30 a.m.–10:00 a.m..

Agenda: Discussion of administrative

matters such as future meetings, budget, and

information items related to the operation of

the NCI Frederick Cancer Research and

Development Center.

Closed: December 11—10 a.m. to recess,

December 12–8:30 a.m. to adjournment.

Agenda/Purpose: Discussion of previous

site visit report and response for the Gene

Regulation and Chromosome Biology

Laboratory and Molecular Aspects of Drug

Design Section both under contract with

ABL—Basic Research Program review held

June 9–10, 1997. The majority of the closed

session will be devoted to a site review of the

Molecular Basis of Carcinogenesis Laboratory

with ABL—Basic Research Program contract.

Contact Person: Donald F. Summers, M.D.,

Acting Executive Secretary, Frederick Cancer

Research and Development Center, P.O. Box

B, Frederick, MD 21702–1201, Telephone:

301–846–5096.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The